Advertisement
Singapore markets closed

  • Straits Times Index

    3,176.51
    -11.15 (-0.35%)
     

  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • Bitcoin USD

    64,326.33
    +953.20 (+1.50%)
     

  • CMC Crypto 200

    1,382.97
    +70.35 (+5.36%)
     

  • S&P 500

    4,969.30
    -41.82 (-0.83%)
     

  • Dow

    37,970.19
    +194.81 (+0.52%)
     

  • Nasdaq

    15,292.59
    -308.91 (-1.98%)
     

  • Gold

    2,409.90
    +11.90 (+0.50%)
     

  • Crude Oil

    83.26
    +0.53 (+0.64%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • FTSE Bursa Malaysia

    1,547.57
    +2.81 (+0.18%)
     

  • Jakarta Composite Index

    7,087.32
    -79.50 (-1.11%)
     

  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

Company News For Aug 21, 2019

Zacks Equity Research

  • Kohl's Corporation’s KSS shares fell 6.9% after the company reported second quarter fiscal 2019 revenues of $4,430 million, lower than the Zacks Consensus Estimate of $4,455 million

  • Medtronic plc’s MDT shares gained 2.6% after the company reported first quarter fiscal 2020 earnings per share of $1.26, surpassing the Zacks Consensus Estimate of $1.18

  • Shares of Baidu, Inc. BIDU rallied 4.3% after the company reported second quarter 2019 earnings per share of $1.47, higher than the Zacks Consensus Estimate of $0.94

  • Shares of Sarepta Therapeutics, Inc. SRPT fell 15.2% afterthe company announced that U.S. Food and Drug Administration (FDA) did not approve its newest treatment for Duchenne muscular dystrophy (DMD)


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Baidu, Inc. (BIDU) : Free Stock Analysis Report
 
Medtronic PLC (MDT) : Free Stock Analysis Report
 
Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report
 
Kohl's Corporation (KSS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research